Literature DB >> 20543864

DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung.

T Shibata1, A Kokubu, M Miyamoto, F Hosoda, M Gotoh, K Tsuta, H Asamura, Y Matsuno, T Kondo, I Imoto, J Inazawa, S Hirohashi.   

Abstract

Lung cancer shows diverse histological subtypes. Large-cell neuroendocrine cell carcinoma and small-cell lung carcinoma show similar histological features and clinical behaviors, and can be classified as high-grade neuroendocrine carcinoma (HGNEC) of the lung. Here we elucidated the molecular classification of pulmonary endocrine tumors by copy-number profiling. We compared alterations of copy number with the clinical outcome of HGNEC and identified a chromosomal gain of the DEK oncogene locus (6p22.3) that was significantly associated with poor prognosis. We further confirmed that DEK overexpression was associated with poor prognosis in a larger set of HGNEC. Downregulation of DEK by small hairpin RNA led to a marked reduction of in vitro colony formation, in vivo tumorigenicity and chemo-resistance, and was associated with loss of lung cancer stem cell markers. Gene expression profiling revealed that DEK downregulation was associated with altered expression of transcriptional regulators, which specifically include known targets of interchromosomal translocations in hematopoietic tumors, and knockdown of these epigenetic modifiers affected colony formation activity. Our study showed that DEK overexpression, partly through an increase in its gene dose, mediates the activity of global transcriptional regulators and is associated with tumor initiation activity and poor prognosis in HGNEC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20543864     DOI: 10.1038/onc.2010.217

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

1.  MicroRNA-592 targets DEK oncogene and suppresses cell growth in the hepatocellular carcinoma cell line HepG2.

Authors:  Xin Li; Wenfeng Zhang; Liya Zhou; Donghui Yue; Xin Su
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 2.  The DEK oncoprotein and its emerging roles in gene regulation.

Authors:  C Sandén; U Gullberg
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

3.  Expression level of DEK in chronic lymphocytic leukemia is regulated by fludarabine and Nutlin-3 depending on p53 status.

Authors:  Dong-Mei Wang; Ling Liu; Lei Fan; Zhi-Jian Zou; Li-Na Zhang; Shu Yang; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2012-10-10       Impact factor: 4.742

4.  Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation.

Authors:  Tatsuhiro Shibata; Akiko Kokubu; Masashi Miyamoto; Yuko Sasajima; Naoya Yamazaki
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

5.  DEK expression in melanocytic lesions.

Authors:  Ferdinand Kappes; Michael S Khodadoust; Limin Yu; David S L Kim; Douglas R Fullen; David M Markovitz; Linglei Ma
Journal:  Hum Pathol       Date:  2011-02-11       Impact factor: 3.466

6.  Future directions and treatment strategies for head and neck squamous cell carcinomas.

Authors:  Trisha M Wise-Draper; David J Draper; J Silvio Gutkind; Alfredo A Molinolo; Kathryn A Wikenheiser-Brokamp; Susanne I Wells
Journal:  Transl Res       Date:  2012-02-28       Impact factor: 7.012

Review 7.  Stacking the DEK: from chromatin topology to cancer stem cells.

Authors:  Lisa M Privette Vinnedge; Ferdinand Kappes; Nicolas Nassar; Susanne I Wells
Journal:  Cell Cycle       Date:  2012-12-19       Impact factor: 4.534

8.  Overexpression of DEK is an indicator of poor prognosis in patients with gastric adenocarcinoma.

Authors:  Yingfu Ou; Rongjun Xia; Fanyong Kong; Xiaokang Zhang; Shengjin Yu; Lili Jiang; Linlin Zheng; Lijuan Lin
Journal:  Oncol Lett       Date:  2016-01-26       Impact factor: 2.967

Review 9.  Concise review: role of DEK in stem/progenitor cell biology.

Authors:  Hal E Broxmeyer; Nirit Mor-Vaknin; Ferdinand Kappes; Maureen Legendre; Anjan K Saha; Xuan Ou; Heather O'Leary; Maegan Capitano; Scott Cooper; David M Markovitz
Journal:  Stem Cells       Date:  2013-08       Impact factor: 6.277

10.  High expression of oncoprotein DEK predicts poor prognosis of small cell lung cancer.

Authors:  Xiaoyan Wang; Lijuan Lin; Xiangshan Ren; Zhenhua Lin; Zhuhu Li; Chunyu Li; Tiefeng Jin
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.